Quantcast

Latest Sirolimus Stories

2009-06-02 16:01:35

U.S. researchers have found an FDA-approved drug that might prevent genetically caused epilepsy also might help prevent more common forms of the condition. Washington University School of Medicine researchers in St. Louis said they found the drug rapamycin may also help prevent forms of epilepsy caused by brain injury. The scientists determined rapamycin blocks brain changes believed to cause seizures in rats. In a paper last year, the same group showed rapamycin prevents brain changes in...

2009-06-02 07:59:59

A drug with potential to prevent epilepsy caused by a genetic condition may also help prevent more common forms of epilepsy caused by brain injury, according to researchers at Washington University School of Medicine in St. Louis. Scientists found that the FDA-approved drug rapamycin blocks brain changes believed to cause seizures in rats. In a paper last year, the same group showed that rapamycin prevents brain changes in mice triggered by one of the most common genetic causes of...

2009-06-01 09:00:00

 REGiMMUNE Corporation today announced that its lead product candidate RGI-2001, in combination with a low-dose of Sirolimus, demonstrated enhanced efficacy in transplantation tolerance induction in models of skin transplantation and acute Graft-versus-Host disease (GvHD). This data is being presented today in a poster titled "Donor-Specific Tolerance Induction by a Liposomal Formulation of KRN7000 (RGI-2001) Alone and in Combination with Low-Dose Sirolimus" at the 2009 American...

2009-06-01 07:16:28

Fox Chase Cancer Center investigators report that a two-drug blockade of mTOR signaling appears safe in metastatic kidney cancer in a phase I trial. Early data suggests that a combination of temsirolimus and bryostatin may be active in patients with rare forms of renal cell cancer, which are less likely to respond to other targeted therapies.Elizabeth Plimack, M.D., M.S., a medical oncologist and attending physician at Fox Chase will report the trial results on Sunday, May 31 at the annual...

2009-05-29 15:30:00

KRX-0401 Demonstrates Impressive Single Agent Efficacy in Patients who Progressed after Failing Treatment Either with a VEGF Receptor Inhibitor or after Treatment with both a VEGF Receptor Inhibitor and an mTOR Inhibitor NEW YORK, May 29 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced data on the clinical activity of KRX-0401 (perifosine), the Company's Akt-inhibitor for cancer, as a treatment for advanced renal cell carcinoma. Abstract #5034,...

2009-05-20 12:41:00

Other Presentations Highlight Pre-clinical Work of Company's Future Pro-healing Technologies BARCELONA, Spain, May 20 /PRNewswire/ -- OrbusNeich announced today that two year follow up data from a single center, randomized clinical study in patients at high risk of restenosis were presented at EuroPCR 2009, demonstrating stable results in patients treated with the company's Genous Bio-engineered R stent, the world's first pro-healing stent, compared with results from patients treated with a...

2009-05-14 14:37:14

Osteoporosis, or bone loss, is a disease that is most common in the elderly population, affecting women more often than men. Until now, it was not clear exactly how the disease develops. Researchers of the Max Delbrck Center for Molecular Medicine (MDC) Berlin-Buch, Germany, have now elucidated a molecular mechanism which regulates the equilibrium between bone formation and bone resorption. Dr. Jeske J. Smink, Dr. Val©rie B©gay, and Professor Achim Leutz were able to show that two...

2009-05-12 08:30:00

NEW BRUNSWICK, N.J., May 12 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) will host a conference call for financial analysts at noon (Eastern Time) on Tuesday, May 19, 2009 to review the primary data from NEVO RES I, the pivotal European trial of the NEVO(TM) Sirolimus-eluting Coronary Stent. NEVO(TM) is the first and only drug-eluting stent utilizing a unique reservoir (RES) technology. Results from this trial will support a design dossier submission for CE Mark approval in...

2009-04-21 19:50:22

Researchers at the University of Chicago Medical Center found that combining 8 ounces of grapefruit juice with the drug rapamycin can increase drug levels. Grapefruit juice can increase blood levels of certain drugs three to five times, Dr. Ezra Cohen, director of the study, said in a statement. This has always been considered a hazard. We wanted to see if, and how much, it could amplify the availability, and perhaps the efficacy of rapamycin, a drug with promise for cancer treatment....

2009-04-21 07:29:00

Data Selected for Presentation Highlights Anti-Tumor effects of KRX-0401 (Perifosine) NEW YORK, April 21 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced multiple presentations of preclinical data highlighting the anti-tumor effects of KRX-0401 (perifosine), the company's lead anti-cancer compound, at the American Association of Cancer Research (AACR) Annual Meeting, being held in Denver, Colorado. Abstracts selected for presentation today, Tuesday,...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related